| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | RNA polymerase II sequence-specific DNA-binding transcription factor recruiting activity | 6.03e-11 | 4 | 6 | 3 | GO:0001010 | |
| GeneOntologyMolecularFunction | lysine-acetylated histone binding | 6.10e-08 | 30 | 6 | 3 | GO:0070577 | |
| GeneOntologyMolecularFunction | acetylation-dependent protein binding | 6.75e-08 | 31 | 6 | 3 | GO:0140033 | |
| GeneOntologyMolecularFunction | modification-dependent protein binding | 2.12e-05 | 206 | 6 | 3 | GO:0140030 | |
| GeneOntologyMolecularFunction | histone binding | 4.49e-05 | 265 | 6 | 3 | GO:0042393 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity, RNA polymerase II-specific | 7.87e-05 | 320 | 6 | 3 | GO:0001227 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity | 8.31e-05 | 326 | 6 | 3 | GO:0001217 | |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity, RNA polymerase II-specific | 4.12e-04 | 560 | 6 | 3 | GO:0001228 | |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity | 4.25e-04 | 566 | 6 | 3 | GO:0001216 | |
| GeneOntologyMolecularFunction | chromatin binding | 9.29e-04 | 739 | 6 | 3 | GO:0003682 | |
| GeneOntologyMolecularFunction | transcription factor binding | 9.81e-04 | 753 | 6 | 3 | GO:0008134 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 3.42e-03 | 1160 | 6 | 3 | GO:0030674 | |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | 4.18e-03 | 1244 | 6 | 3 | GO:0000978 | |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | 4.45e-03 | 1271 | 6 | 3 | GO:0000987 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | 5.35e-03 | 1356 | 6 | 3 | GO:0060090 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | 6.00e-03 | 1412 | 6 | 3 | GO:0000981 | |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | 6.58e-03 | 1459 | 6 | 3 | GO:0000977 | |
| GeneOntologyBiologicalProcess | negative regulation of endodermal cell fate specification | 2.74e-11 | 4 | 5 | 3 | GO:0042664 | |
| GeneOntologyBiologicalProcess | regulation of endodermal cell fate specification | 6.84e-11 | 5 | 5 | 3 | GO:0042663 | |
| GeneOntologyBiologicalProcess | negative regulation of endodermal cell differentiation | 1.37e-10 | 6 | 5 | 3 | GO:1903225 | |
| GeneOntologyBiologicalProcess | negative regulation of cell fate specification | 3.83e-10 | 8 | 5 | 3 | GO:0009996 | |
| GeneOntologyBiologicalProcess | regulation of endodermal cell differentiation | 8.20e-10 | 10 | 5 | 3 | GO:1903224 | |
| GeneOntologyBiologicalProcess | endodermal cell fate specification | 1.13e-09 | 11 | 5 | 3 | GO:0001714 | |
| GeneOntologyBiologicalProcess | cell dedifferentiation | 3.11e-09 | 15 | 5 | 3 | GO:0043697 | |
| GeneOntologyBiologicalProcess | dedifferentiation | 3.11e-09 | 15 | 5 | 3 | GO:0043696 | |
| GeneOntologyBiologicalProcess | negative regulation of cell fate commitment | 4.65e-09 | 17 | 5 | 3 | GO:0010454 | |
| GeneOntologyBiologicalProcess | endodermal cell fate commitment | 5.57e-09 | 18 | 5 | 3 | GO:0001711 | |
| GeneOntologyBiologicalProcess | regulation of stem cell division | 5.57e-09 | 18 | 5 | 3 | GO:2000035 | |
| GeneOntologyBiologicalProcess | mesodermal cell fate commitment | 1.21e-08 | 23 | 5 | 3 | GO:0001710 | |
| GeneOntologyBiologicalProcess | regulation of cell fate specification | 2.49e-08 | 29 | 5 | 3 | GO:0042659 | |
| GeneOntologyBiologicalProcess | negative regulation of stem cell differentiation | 3.72e-08 | 33 | 5 | 3 | GO:2000737 | |
| GeneOntologyBiologicalProcess | mesodermal cell differentiation | 4.47e-08 | 35 | 5 | 3 | GO:0048333 | |
| GeneOntologyBiologicalProcess | cell fate commitment involved in formation of primary germ layer | 5.30e-08 | 37 | 5 | 3 | GO:0060795 | |
| GeneOntologyBiologicalProcess | endodermal cell differentiation | 5.75e-08 | 38 | 5 | 3 | GO:0035987 | |
| GeneOntologyBiologicalProcess | endoderm formation | 1.26e-07 | 49 | 5 | 3 | GO:0001706 | |
| GeneOntologyBiologicalProcess | stem cell division | 1.26e-07 | 49 | 5 | 3 | GO:0017145 | |
| GeneOntologyBiologicalProcess | regulation of cell fate commitment | 1.60e-07 | 53 | 5 | 3 | GO:0010453 | |
| GeneOntologyBiologicalProcess | stem cell differentiation | 2.35e-07 | 306 | 5 | 4 | GO:0048863 | |
| GeneOntologyBiologicalProcess | negative regulation of BMP signaling pathway | 5.59e-07 | 80 | 5 | 3 | GO:0030514 | |
| GeneOntologyBiologicalProcess | mesoderm formation | 6.02e-07 | 82 | 5 | 3 | GO:0001707 | |
| GeneOntologyBiologicalProcess | mesoderm morphogenesis | 6.96e-07 | 86 | 5 | 3 | GO:0048332 | |
| GeneOntologyBiologicalProcess | negative regulation of developmental process | 7.18e-07 | 1220 | 5 | 5 | GO:0051093 | |
| GeneOntologyBiologicalProcess | endoderm development | 7.46e-07 | 88 | 5 | 3 | GO:0007492 | |
| GeneOntologyBiologicalProcess | regulation of stem cell differentiation | 1.07e-06 | 99 | 5 | 3 | GO:2000736 | |
| GeneOntologyBiologicalProcess | somatic stem cell population maintenance | 1.39e-06 | 108 | 5 | 3 | GO:0035019 | |
| GeneOntologyBiologicalProcess | anatomical structure formation involved in morphogenesis | 1.91e-06 | 1483 | 5 | 5 | GO:0048646 | |
| GeneOntologyBiologicalProcess | cell fate specification | 2.05e-06 | 123 | 5 | 3 | GO:0001708 | |
| GeneOntologyBiologicalProcess | formation of primary germ layer | 2.10e-06 | 124 | 5 | 3 | GO:0001704 | |
| GeneOntologyBiologicalProcess | regulation of BMP signaling pathway | 2.48e-06 | 131 | 5 | 3 | GO:0030510 | |
| GeneOntologyBiologicalProcess | response to retinoic acid | 2.48e-06 | 131 | 5 | 3 | GO:0032526 | |
| GeneOntologyBiologicalProcess | negative regulation of cellular response to growth factor stimulus | 3.73e-06 | 150 | 5 | 3 | GO:0090288 | |
| GeneOntologyBiologicalProcess | positive regulation of mitotic cell cycle | 4.12e-06 | 155 | 5 | 3 | GO:0045931 | |
| GeneOntologyBiologicalProcess | mesoderm development | 4.28e-06 | 157 | 5 | 3 | GO:0007498 | |
| GeneOntologyBiologicalProcess | tissue morphogenesis | 8.42e-06 | 750 | 5 | 4 | GO:0048729 | |
| GeneOntologyBiologicalProcess | BMP signaling pathway | 8.46e-06 | 197 | 5 | 3 | GO:0030509 | |
| GeneOntologyBiologicalProcess | regulation of cell division | 8.99e-06 | 201 | 5 | 3 | GO:0051302 | |
| GeneOntologyBiologicalProcess | gastrulation | 1.05e-05 | 212 | 5 | 3 | GO:0007369 | |
| GeneOntologyBiologicalProcess | response to BMP | 1.10e-05 | 215 | 5 | 3 | GO:0071772 | |
| GeneOntologyBiologicalProcess | cellular response to BMP stimulus | 1.10e-05 | 215 | 5 | 3 | GO:0071773 | |
| GeneOntologyBiologicalProcess | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1.15e-05 | 218 | 5 | 3 | GO:0090101 | |
| GeneOntologyBiologicalProcess | stem cell population maintenance | 1.47e-05 | 237 | 5 | 3 | GO:0019827 | |
| GeneOntologyBiologicalProcess | negative regulation of cell differentiation | 1.55e-05 | 875 | 5 | 4 | GO:0045596 | |
| GeneOntologyBiologicalProcess | maintenance of cell number | 1.57e-05 | 242 | 5 | 3 | GO:0098727 | |
| GeneOntologyBiologicalProcess | cell fate commitment | 4.26e-05 | 338 | 5 | 3 | GO:0045165 | |
| GeneOntologyBiologicalProcess | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 4.60e-05 | 347 | 5 | 3 | GO:0090092 | |
| GeneOntologyBiologicalProcess | positive regulation of cell population proliferation | 5.26e-05 | 1190 | 5 | 4 | GO:0008284 | |
| GeneOntologyBiologicalProcess | positive regulation of cell cycle | 7.41e-05 | 407 | 5 | 3 | GO:0045787 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to growth factor stimulus | 7.68e-05 | 412 | 5 | 3 | GO:0090287 | |
| GeneOntologyBiologicalProcess | transforming growth factor beta receptor superfamily signaling pathway | 9.66e-05 | 445 | 5 | 3 | GO:0141091 | |
| GeneOntologyBiologicalProcess | cell surface receptor protein serine/threonine kinase signaling pathway | 1.22e-04 | 482 | 5 | 3 | GO:0007178 | |
| GeneOntologyBiologicalProcess | regulation of mitotic cell cycle | 2.28e-04 | 594 | 5 | 3 | GO:0007346 | |
| GeneOntologyBiologicalProcess | cell division | 3.65e-04 | 697 | 5 | 3 | GO:0051301 | |
| GeneOntologyBiologicalProcess | embryonic morphogenesis | 3.90e-04 | 713 | 5 | 3 | GO:0048598 | |
| GeneOntologyBiologicalProcess | cellular response to growth factor stimulus | 6.55e-04 | 850 | 5 | 3 | GO:0071363 | |
| GeneOntologyBiologicalProcess | response to growth factor | 7.33e-04 | 883 | 5 | 3 | GO:0070848 | |
| GeneOntologyBiologicalProcess | mitotic cell cycle | 1.10e-03 | 1014 | 5 | 3 | GO:0000278 | |
| GeneOntologyBiologicalProcess | negative regulation of transcription by RNA polymerase II | 1.23e-03 | 1053 | 5 | 3 | GO:0000122 | |
| GeneOntologyBiologicalProcess | response to lipid | 1.49e-03 | 1126 | 5 | 3 | GO:0033993 | |
| GeneOntologyBiologicalProcess | enzyme-linked receptor protein signaling pathway | 1.74e-03 | 1186 | 5 | 3 | GO:0007167 | |
| GeneOntologyBiologicalProcess | regulation of cell cycle | 2.05e-03 | 1256 | 5 | 3 | GO:0051726 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | 2.75e-03 | 1390 | 5 | 3 | GO:0045944 | |
| GeneOntologyBiologicalProcess | negative regulation of DNA-templated transcription | 2.81e-03 | 1399 | 5 | 3 | GO:0045892 | |
| GeneOntologyBiologicalProcess | negative regulation of RNA biosynthetic process | 2.89e-03 | 1413 | 5 | 3 | GO:1902679 | |
| GeneOntologyBiologicalProcess | embryo development | 3.03e-03 | 1437 | 5 | 3 | GO:0009790 | |
| GeneOntologyBiologicalProcess | positive regulation of nervous system development | 3.93e-03 | 418 | 5 | 2 | GO:0051962 | |
| GeneOntologyBiologicalProcess | regulation of angiogenesis | 3.97e-03 | 420 | 5 | 2 | GO:0045765 | |
| GeneOntologyBiologicalProcess | regulation of vasculature development | 4.16e-03 | 430 | 5 | 2 | GO:1901342 | |
| GeneOntologyBiologicalProcess | regulation of neuron projection development | 8.28e-03 | 612 | 5 | 2 | GO:0010975 | |
| GeneOntologyBiologicalProcess | cellular component disassembly | 8.41e-03 | 617 | 5 | 2 | GO:0022411 | |
| GeneOntologyBiologicalProcess | regulation of nervous system development | 8.63e-03 | 625 | 5 | 2 | GO:0051960 | |
| GeneOntologyCellularComponent | condensed chromosome | 3.07e-05 | 307 | 5 | 3 | GO:0000793 | |
| GeneOntologyCellularComponent | chromatin | 3.18e-03 | 1480 | 5 | 3 | GO:0000785 | |
| MousePheno | absent primitive endoderm | 1.84e-09 | 9 | 5 | 3 | MP:0011185 | |
| MousePheno | absent extraembryonic ectoderm | 9.98e-09 | 15 | 5 | 3 | MP:0002583 | |
| MousePheno | absent embryonic epiblast | 1.23e-08 | 16 | 5 | 3 | MP:0011184 | |
| MousePheno | abnormal primitive endoderm morphology | 4.44e-08 | 24 | 5 | 3 | MP:0011183 | |
| MousePheno | abnormal inner cell mass apoptosis | 9.85e-08 | 31 | 5 | 3 | MP:0010380 | |
| MousePheno | abnormal extraembryonic ectoderm morphology | 9.85e-08 | 31 | 5 | 3 | MP:0010736 | |
| MousePheno | disorganized extraembryonic tissue | 1.43e-07 | 35 | 5 | 3 | MP:0002582 | |
| MousePheno | abnormal embryonic epiblast morphology | 2.92e-06 | 94 | 5 | 3 | MP:0003886 | |
| MousePheno | abnormal bilaminar embryonic disk morphology | 3.73e-06 | 102 | 5 | 3 | MP:0012103 | |
| MousePheno | abnormal inner cell mass morphology | 5.08e-06 | 113 | 5 | 3 | MP:0002718 | |
| MousePheno | abnormal embryonic tissue cell apoptosis | 2.06e-05 | 180 | 5 | 3 | MP:0013503 | |
| MousePheno | abnormal blastocyst morphology | 6.12e-05 | 259 | 5 | 3 | MP:0004957 | |
| MousePheno | abnormal preimplantation embryo morphology | 7.97e-05 | 283 | 5 | 3 | MP:0014137 | |
| MousePheno | abnormal embryonic tissue physiology | 9.20e-05 | 297 | 5 | 3 | MP:0008932 | |
| MousePheno | embryonic lethality between implantation and somite formation, complete penetrance | 1.06e-04 | 311 | 5 | 3 | MP:0011096 | |
| MousePheno | embryonic lethality between implantation and somite formation | 1.38e-04 | 340 | 5 | 3 | MP:0006205 | |
| MousePheno | embryonic lethality between implantation and placentation, complete penetrance | 4.46e-04 | 506 | 5 | 3 | MP:0011095 | |
| MousePheno | embryonic lethality between implantation and placentation | 6.18e-04 | 565 | 5 | 3 | MP:0009850 | |
| MousePheno | embryonic lethality prior to organogenesis, complete penetrance | 1.54e-03 | 772 | 5 | 3 | MP:0014259 | |
| MousePheno | embryonic lethality prior to tooth bud stage, complete penetrance | 1.58e-03 | 779 | 5 | 3 | MP:0014257 | |
| MousePheno | abnormal extraembryonic tissue morphology | 2.47e-03 | 908 | 5 | 3 | MP:0002086 | |
| MousePheno | abnormal embryonic tissue morphology | 4.49e-03 | 1116 | 5 | 3 | MP:0002085 | |
| MousePheno | embryonic lethality prior to organogenesis | 5.58e-03 | 1204 | 5 | 3 | MP:0013292 | |
| MousePheno | abnormal apoptosis | 7.79e-03 | 1353 | 5 | 3 | MP:0001648 | |
| MousePheno | abnormal programmed cell death | 7.90e-03 | 1360 | 5 | 3 | MP:0014355 | |
| MousePheno | embryonic lethality prior to tooth bud stage | 8.29e-03 | 1383 | 5 | 3 | MP:0013293 | |
| Domain | Homeobox | 1.91e-05 | 234 | 5 | 3 | PF00046 | |
| Domain | HOMEOBOX_1 | 1.96e-05 | 236 | 5 | 3 | PS00027 | |
| Domain | HOX | 1.98e-05 | 237 | 5 | 3 | SM00389 | |
| Domain | Homeobox_dom | 2.03e-05 | 239 | 5 | 3 | IPR001356 | |
| Domain | HOMEOBOX_2 | 2.03e-05 | 239 | 5 | 3 | PS50071 | |
| Domain | TSP_1 | 1.11e-04 | 63 | 5 | 2 | PF00090 | |
| Domain | TSP1_rpt | 1.18e-04 | 65 | 5 | 2 | IPR000884 | |
| Domain | TSP1 | 1.18e-04 | 65 | 5 | 2 | PS50092 | |
| Domain | TSP1 | 1.18e-04 | 65 | 5 | 2 | SM00209 | |
| Domain | Homeodomain-like | 3.04e-03 | 332 | 5 | 2 | IPR009057 | |
| Pathway | WP_WNT_SIGNALING_PATHWAY_AND_PLURIPOTENCY | 3.53e-06 | 101 | 5 | 3 | MM15829 | |
| Pathway | WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY | 9.34e-05 | 301 | 5 | 3 | MM15983 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 25825768 | ||
| Pubmed | Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation. | 2.85e-12 | 3 | 6 | 3 | 31891567 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 23200040 | ||
| Pubmed | Heterogeneities in Nanog Expression Drive Stable Commitment to Pluripotency in the Mouse Blastocyst. | 2.85e-12 | 3 | 6 | 3 | 25753417 | |
| Pubmed | Stochastic promoter activation affects Nanog expression variability in mouse embryonic stem cells. | 2.85e-12 | 3 | 6 | 3 | 25410303 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 24929238 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 19447925 | ||
| Pubmed | Selenium Augments microRNA Directed Reprogramming of Fibroblasts to Cardiomyocytes via Nanog. | 2.85e-12 | 3 | 6 | 3 | 26975336 | |
| Pubmed | Nanog suppresses cell migration by downregulating thymosin β4 and Rnd3. | 2.85e-12 | 3 | 6 | 3 | 23329853 | |
| Pubmed | The pluripotency factor NANOG controls primitive hematopoiesis and directly regulates Tal1. | 2.85e-12 | 3 | 6 | 3 | 30814124 | |
| Pubmed | Nanog and transcriptional networks in embryonic stem cell pluripotency. | 2.85e-12 | 3 | 6 | 3 | 17211451 | |
| Pubmed | The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. | 2.85e-12 | 3 | 6 | 3 | 23770853 | |
| Pubmed | Identification of two distinct transactivation domains in the pluripotency sustaining factor nanog. | 2.85e-12 | 3 | 6 | 3 | 14728807 | |
| Pubmed | Locating and Characterizing a Transgene Integration Site by Nanopore Sequencing. | 2.85e-12 | 3 | 6 | 3 | 30837263 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 15502159 | ||
| Pubmed | NANOG alone induces germ cells in primed epiblast in vitro by activation of enhancers. | 2.85e-12 | 3 | 6 | 3 | 26751055 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 20539761 | ||
| Pubmed | Isolation and characterization of the murine Nanog gene promoter. | 2.85e-12 | 3 | 6 | 3 | 15916719 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 25173648 | ||
| Pubmed | Distinct Contributions of Tryptophan Residues within the Dimerization Domain to Nanog Function. | 2.85e-12 | 3 | 6 | 3 | 27939294 | |
| Pubmed | Epigenetic regulation of Nanog gene in embryonic stem and trophoblast stem cells. | 2.85e-12 | 3 | 6 | 3 | 17352742 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 33334884 | ||
| Pubmed | The molecular logic of Nanog-induced self-renewal in mouse embryonic stem cells. | 2.85e-12 | 3 | 6 | 3 | 30846691 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 21499299 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 20574542 | ||
| Pubmed | lincRNAs act in the circuitry controlling pluripotency and differentiation. | 2.85e-12 | 3 | 6 | 3 | 21874018 | |
| Pubmed | Generation of germline-competent induced pluripotent stem cells. | 2.85e-12 | 3 | 6 | 3 | 17554338 | |
| Pubmed | Cell signalling regulates dynamics of Nanog distribution in embryonic stem cell populations. | 2.85e-12 | 3 | 6 | 3 | 23054952 | |
| Pubmed | Multiple phases in regulation of Nanog expression during pre-implantation development. | 2.85e-12 | 3 | 6 | 3 | 26660234 | |
| Pubmed | Nanog retrotransposed genes with functionally conserved open reading frames. | 2.85e-12 | 3 | 6 | 3 | 16845474 | |
| Pubmed | Nanog overcomes reprogramming barriers and induces pluripotency in minimal conditions. | 2.85e-12 | 3 | 6 | 3 | 21194951 | |
| Pubmed | Phosphorylation of NANOG by casein kinase I regulates embryonic stem cell self-renewal. | 2.85e-12 | 3 | 6 | 3 | 33107035 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 23178592 | ||
| Pubmed | Stochastic NANOG fluctuations allow mouse embryonic stem cells to explore pluripotency. | 2.85e-12 | 3 | 6 | 3 | 25005472 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 18584034 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 24681518 | ||
| Pubmed | Nanog-independent reprogramming to iPSCs with canonical factors. | 2.85e-12 | 3 | 6 | 3 | 24527385 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 21969378 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 16773043 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 18086680 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 20661723 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 29245050 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 23665121 | ||
| Pubmed | Forced expression of Nanog in hematopoietic stem cells results in a gammadeltaT-cell disorder. | 2.85e-12 | 3 | 6 | 3 | 17360937 | |
| Pubmed | Ectopic overexpression of Nanog induces tumorigenesis in non-tumorous fibroblasts. | 2.85e-12 | 3 | 6 | 3 | 26733157 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 22337995 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 22388986 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 21187909 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 16313224 | ||
| Pubmed | Crystal structure and DNA binding of the homeodomain of the stem cell transcription factor Nanog. | 2.85e-12 | 3 | 6 | 3 | 18177668 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 35976266 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 26549484 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 23071603 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 16791199 | ||
| Pubmed | Functional analysis of two Sp1/Sp3 binding sites in murine Nanog gene promoter. | 2.85e-12 | 3 | 6 | 3 | 16541131 | |
| Pubmed | Expression of Nanog gene promotes NIH3T3 cell proliferation. | 2.85e-12 | 3 | 6 | 3 | 16259959 | |
| Pubmed | Role of Nanog in the maintenance of marrow stromal stem cells during post natal bone regeneration. | 2.85e-12 | 3 | 6 | 3 | 22142851 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 16501172 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 18290762 | ||
| Pubmed | NANOG amplifies STAT3 activation and they synergistically induce the naive pluripotent program. | 2.85e-12 | 3 | 6 | 3 | 24462001 | |
| Pubmed | Effect of Nanog overexpression on the metastatic potential of a mouse melanoma cell line B16-BL6. | 2.85e-12 | 3 | 6 | 3 | 33665763 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 12609610 | ||
| Pubmed | Reprogramming of mouse fibroblasts into induced pluripotent stem cells with Nanog. | 2.85e-12 | 3 | 6 | 3 | 23333380 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 16790525 | ||
| Pubmed | Primitive endoderm differentiates via a three-step mechanism involving Nanog and RTK signaling. | 2.85e-12 | 3 | 6 | 3 | 22172669 | |
| Pubmed | Heparan sulfate regulates self-renewal and pluripotency of embryonic stem cells. | 2.85e-12 | 3 | 6 | 3 | 18024963 | |
| Pubmed | Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. | 2.85e-12 | 3 | 6 | 3 | 19582141 | |
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 27125671 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 18442017 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 24227785 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 21119109 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 32145514 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 26760119 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 19703398 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 22028025 | ||
| Pubmed | 2.85e-12 | 3 | 6 | 3 | 17204467 | ||
| Pubmed | Nanog safeguards pluripotency and mediates germline development. | 2.85e-12 | 3 | 6 | 3 | 18097409 | |
| Pubmed | Context-Dependent Functions of NANOG Phosphorylation in Pluripotency and Reprogramming. | 2.85e-12 | 3 | 6 | 3 | 28457890 | |
| Pubmed | CrxOS maintains the self-renewal capacity of murine embryonic stem cells. | 2.85e-12 | 3 | 6 | 3 | 19800316 | |
| Pubmed | Nanog Fluctuations in Embryonic Stem Cells Highlight the Problem of Measurement in Cell Biology. | 2.85e-12 | 3 | 6 | 3 | 28636920 | |
| Pubmed | Requirement of Nanog dimerization for stem cell self-renewal and pluripotency. | 2.85e-12 | 3 | 6 | 3 | 18436640 | |
| Pubmed | Nanog is dispensable for the generation of induced pluripotent stem cells. | 2.85e-12 | 3 | 6 | 3 | 24461999 | |
| Pubmed | Nanog-dependent feedback loops regulate murine embryonic stem cell heterogeneity. | 2.85e-12 | 3 | 6 | 3 | 23103910 | |
| Pubmed | Aggregation of embryonic stem cells induces Nanog repression and primitive endoderm differentiation. | 2.85e-12 | 3 | 6 | 3 | 15494369 | |
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 19366700 | ||
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 25743411 | ||
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 31262352 | ||
| Pubmed | Prion protein expression regulates embryonic stem cell pluripotency and differentiation. | 1.14e-11 | 4 | 6 | 3 | 21483752 | |
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 16166633 | ||
| Pubmed | Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter. | 1.14e-11 | 4 | 6 | 3 | 28093523 | |
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 22315219 | ||
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 21304588 | ||
| Pubmed | Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. | 1.14e-11 | 4 | 6 | 3 | 16894029 | |
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 33058869 | ||
| Pubmed | GATA-1 directly regulates Nanog in mouse embryonic stem cells. | 1.14e-11 | 4 | 6 | 3 | 26296469 | |
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 17518637 | ||
| Pubmed | Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells. | 1.14e-11 | 4 | 6 | 3 | 21810410 | |
| Pubmed | Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. | 1.14e-11 | 4 | 6 | 3 | 21490431 | |
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 22787153 | ||
| Pubmed | 1.14e-11 | 4 | 6 | 3 | 20071344 | ||
| Cytoband | Ensembl 112 genes in cytogenetic band chr12p13 | 8.66e-04 | 353 | 6 | 2 | chr12p13 | |
| GeneFamily | NKL subclass homeoboxes and pseudogenes | 4.84e-07 | 67 | 5 | 3 | 519 | |
| Coexpression | TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_DN | 7.99e-10 | 10 | 6 | 3 | MM741 | |
| Coexpression | MIKKELSEN_PLURIPOTENT_STATE_UP | 2.42e-09 | 14 | 6 | 3 | MM810 | |
| Coexpression | PASINI_SUZ12_TARGETS_UP | 2.10e-06 | 125 | 6 | 3 | MM1065 | |
| Coexpression | RAO_BOUND_BY_SALL4 | 1.62e-05 | 247 | 6 | 3 | MM1081 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP | 2.04e-05 | 267 | 6 | 3 | MM984 | |
| Coexpression | BOSCO_ALLERGEN_INDUCED_TH2_ASSOCIATED_MODULE | 4.81e-04 | 150 | 6 | 2 | M2526 | |
| Coexpression | DESCARTES_FETAL_LIVER_STELLATE_CELLS | 5.47e-04 | 160 | 6 | 2 | M40233 | |
| Coexpression | GSE19374_UNINF_VS_LISTERIA_INFECTED_MACROPHAGE_UP | 8.26e-04 | 197 | 6 | 2 | M7264 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Mesoderm_top-relative-expression-ranked_2500_k-means-cluster#3 | 2.40e-05 | 768 | 6 | 4 | ratio_SC_vs_MESO_2500_K3 | |
| CoexpressionAtlas | AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500_k-means-cluster#5 | 2.51e-05 | 232 | 6 | 3 | Arv_SC-hpx_blastocyst_500_K5 | |
| CoexpressionAtlas | AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500_k-means-cluster#1 | 2.51e-05 | 232 | 6 | 3 | Arv_SC-H9hpx_500_K1 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_induced-DefinitiveEndoderm_top-relative-expression-ranked_1000 | 6.30e-05 | 981 | 6 | 4 | PCBC_DE_1000 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Ectoderm_top-relative-expression-ranked_500_k-means-cluster#2 | 6.74e-05 | 323 | 6 | 3 | ratio_SC_vs_ECTO_500_K2 | |
| CoexpressionAtlas | ratio_StemCell_vs_EmbryoidBody_top-relative-expression-ranked_500_k-means-cluster#5 | 9.77e-05 | 366 | 6 | 3 | ratio_SC_vs_EB_500_K5 | |
| CoexpressionAtlas | ratio_StemCell-derived-from_CD34-iPSC_vs_StemCell-fibro_top-relative-expression-ranked_2500_k-means-cluster#4 | 2.02e-04 | 468 | 6 | 3 | ratio_SC-cbCD34_vs_SC-fibro_2500_K4 | |
| CoexpressionAtlas | ratio_EmbryoidBody-derived-from_CD34-iPSC_vs_EmbryoidBody-fibro_top-relative-expression-ranked_2500_k-means-cluster#2 | 2.25e-04 | 485 | 6 | 3 | ratio_EB-cbCD34_vs_EB-fibro_2500_K2 | |
| CoexpressionAtlas | ratio_StemCell-blastocyst_vs_StemCell-fibro_top-relative-expression-ranked_2500_k-means-cluster#1 | 2.26e-04 | 486 | 6 | 3 | ratio_SC-blastocyst_vs_SC-fibro_2500_K1 | |
| CoexpressionAtlas | ratio_EmbryoidBody-derived-from_CD34-iPSC_vs_EmbryoidBody-blastocyst_top-relative-expression-ranked_2500_k-means-cluster#3 | 2.26e-04 | 486 | 6 | 3 | ratio_EB-cbCD34_vs_EB-blastocyst_2500_K3 | |
| CoexpressionAtlas | ratio_StemCell-fibro_vs_StemCell-blastocyst_top-relative-expression-ranked_2500_k-means-cluster#1 | 2.32e-04 | 490 | 6 | 3 | ratio_SC-fibro_vs_SC-blastocyst_2500_K1 | |
| CoexpressionAtlas | AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500 | 2.35e-04 | 492 | 6 | 3 | Arv_SC-H9hpx_500 | |
| CoexpressionAtlas | AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500 | 2.35e-04 | 492 | 6 | 3 | Arv_SC-hpx_blastocyst_500 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Ectoderm_top-relative-expression-ranked_500 | 2.35e-04 | 492 | 6 | 3 | PCBC_ratio_SC_vs_ECTO_500 | |
| CoexpressionAtlas | ratio_StemCell_vs_EmbryoidBody_top-relative-expression-ranked_500 | 2.38e-04 | 494 | 6 | 3 | PCBC_ratio_SC_vs_EB_500 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_StemCell_CD34+_top-relative-expression-ranked_500 | 2.38e-04 | 494 | 6 | 3 | PCBC_SC_CD34+_500 | |
| CoexpressionAtlas | AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_1000_k-means-cluster#5 | 2.54e-04 | 505 | 6 | 3 | Arv_SC-H9hpx_1000_K5 | |
| CoexpressionAtlas | ratio_EmbryoidBody-fibro_vs_EmbryoidBody-derived-from_CD34-iPSC_top-relative-expression-ranked_2500_k-means-cluster#2 | 2.59e-04 | 509 | 6 | 3 | ratio_EB-fibro_vs_EB-cbCD34_2500_K2 | |
| CoexpressionAtlas | AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_1000_k-means-cluster#3 | 2.61e-04 | 510 | 6 | 3 | Arv_SC-hpx_blastocyst_1000_K3 | |
| CoexpressionAtlas | ratio_StemCell-blastocyst_vs_cbCD34_top-relative-expression-ranked_2500_k-means-cluster#1 | 2.69e-04 | 515 | 6 | 3 | ratio_SC-blastocyst_vs_cbCD34_2500_K1 | |
| CoexpressionAtlas | ratio_EmbryoidBody-fibro_vs_EmbryoidBody-blastocyst_top-relative-expression-ranked_2500_k-means-cluster#1 | 2.73e-04 | 518 | 6 | 3 | ratio_EB-fibro_vs_EB-blastocyst_2500_K1 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Ectoderm_top-relative-expression-ranked_1000_k-means-cluster#1 | 2.81e-04 | 523 | 6 | 3 | ratio_SC_vs_ECTO_1000_K1 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Mesoderm_top-relative-expression-ranked_1000_k-means-cluster#5 | 3.09e-04 | 540 | 6 | 3 | ratio_SC_vs_MESO_1000_K5 | |
| CoexpressionAtlas | AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000_k-means-cluster#2 | 3.33e-04 | 554 | 6 | 3 | Arv_SC_fibroblast_1000_K2 | |
| CoexpressionAtlas | AravindRamakr_StemCell-HD_top-relative-expression-ranked_1000_k-means-cluster#1 | 3.38e-04 | 557 | 6 | 3 | Arv_SC-HD_1000_K1 | |
| CoexpressionAtlas | ratio_StemCell_vs_EmbryoidBody_top-relative-expression-ranked_1000_k-means-cluster#2 | 4.49e-04 | 613 | 6 | 3 | ratio_SC_vs_EB_1000_K2 | |
| CoexpressionAtlas | JC_iEC_top-relative-expression-ranked_1000_k-means-cluster#4 | 6.82e-04 | 145 | 6 | 2 | JC_iEC_1000_K4 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Ectoderm_top-relative-expression-ranked_2500_k-means-cluster#2 | 1.21e-03 | 860 | 6 | 3 | ratio_SC_vs_ECTO_2500_K2 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#5_top-relative-expression-ranked_1000 | 1.25e-03 | 197 | 6 | 2 | gudmap_developingGonad_e16.5_epididymis_1000_k5 | |
| CoexpressionAtlas | AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_2500_k-means-cluster#2 | 1.59e-03 | 945 | 6 | 3 | Arv_SC-hpx_blastocyst_2500_K2 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_inducedDefinitiveEndoderm_fromFibroblast-derived-iPSC_top-relative-expression-ranked_1000 | 1.75e-03 | 977 | 6 | 3 | PCBC_DE_fibroblast_1000 | |
| CoexpressionAtlas | ratio_StemCell_vs_EmbryoidBody_top-relative-expression-ranked_2500_k-means-cluster#5 | 1.75e-03 | 978 | 6 | 3 | ratio_SC_vs_EB_2500_K5 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#5_top-relative-expression-ranked_1000 | 1.76e-03 | 234 | 6 | 2 | gudmap_developingGonad_e18.5_epididymis_1000_k5 | |
| CoexpressionAtlas | AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_2500_k-means-cluster#5 | 1.77e-03 | 981 | 6 | 3 | Arv_SC-H9hpx_2500_K5 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_inducedDefinitiveEndoderm_fromBlastocyst-derived-iPSC_top-relative-expression-ranked_1000 | 1.77e-03 | 981 | 6 | 3 | PCBC_DE_blastocyst_1000 | |
| CoexpressionAtlas | ratio_StemCell_vs_EmbryoidBody_top-relative-expression-ranked_1000 | 1.79e-03 | 984 | 6 | 3 | PCBC_ratio_SC_vs_EB_1000 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_StemCell_CD34+_top-relative-expression-ranked_1000 | 1.79e-03 | 984 | 6 | 3 | PCBC_SC_CD34+_1000 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Ectoderm_top-relative-expression-ranked_1000 | 1.79e-03 | 984 | 6 | 3 | PCBC_ratio_SC_vs_ECTO_1000 | |
| CoexpressionAtlas | AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000 | 1.80e-03 | 986 | 6 | 3 | Arv_SC_fibroblast_1000 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000 | 1.80e-03 | 986 | 6 | 3 | PCBC_SC_fibroblast_1000 | |
| CoexpressionAtlas | AravindRamakr_StemCell-HD_top-relative-expression-ranked_1000 | 1.80e-03 | 986 | 6 | 3 | Arv_SC-HD_1000 | |
| CoexpressionAtlas | AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_1000 | 1.80e-03 | 987 | 6 | 3 | Arv_SC-H9hpx_1000 | |
| CoexpressionAtlas | AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_1000 | 1.80e-03 | 987 | 6 | 3 | Arv_SC-hpx_blastocyst_1000 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_StemCell_top-relative-expression-ranked_1000 | 1.81e-03 | 989 | 6 | 3 | PCBC_SC_1000 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Mesoderm_top-relative-expression-ranked_1000 | 1.83e-03 | 993 | 6 | 3 | PCBC_ratio_SC_vs_MESO-5_1000 | |
| CoexpressionAtlas | Progenitor-Cell-Biology-Consortium_StemCell_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_1000 | 1.83e-03 | 993 | 6 | 3 | PCBC_SC_blastocyst_1000 | |
| CoexpressionAtlas | AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_2500_k-means-cluster#2 | 2.52e-03 | 1108 | 6 | 3 | Arv_SC_fibroblast_2500_K2 | |
| CoexpressionAtlas | AravindRamakr_StemCell-HD_top-relative-expression-ranked_2500_k-means-cluster#2 | 2.55e-03 | 1113 | 6 | 3 | Arv_SC-HD_2500_K2 | |
| CoexpressionAtlas | ratio_StemCell_vs_induced-Mesoderm_top-relative-expression-ranked_500_k-means-cluster#5 | 2.78e-03 | 295 | 6 | 2 | ratio_SC_vs_MESO_500_K5 | |
| CoexpressionAtlas | AravindRamakr_StemCell-LF_top-relative-expression-ranked_2500_k-means-cluster#5 | 2.81e-03 | 1152 | 6 | 3 | Arv_SC-LF_2500_K5 | |
| CoexpressionAtlas | JC_iEC_top-relative-expression-ranked_2500_k-means-cluster#2 | 3.18e-03 | 316 | 6 | 2 | JC_iEC_2500_K2 | |
| CoexpressionAtlas | AravindRamakr_StemCell-LF_top-relative-expression-ranked_500_k-means-cluster#3 | 3.72e-03 | 342 | 6 | 2 | Arv_SC-LF_500_K3 | |
| CoexpressionAtlas | dev lower uro neuro_e15.5_PelvicGanglion_Sox10_top-relative-expression-ranked_500 | 4.36e-03 | 371 | 6 | 2 | gudmap_dev lower uro neuro_e15.5_PelvicGanglion_Sox10_500 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_top-relative-expression-ranked_500 | 5.74e-03 | 427 | 6 | 2 | DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_500 | |
| ToppCell | TCGA-Testes|World / Sample_Type by Project: Shred V9 | 1.20e-04 | 128 | 6 | 2 | a09b0e221b8749510002304e4d34d6a2eb8867e9 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.99e-04 | 165 | 6 | 2 | cd8de98af8a1a8a6c81d71fae807cc07f319f4c9 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.99e-04 | 165 | 6 | 2 | 4f83ac71efc57be3668d8db1e62bad05dc6a5e2b | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.21e-04 | 174 | 6 | 2 | 015d3742d3d79a57413a333f00ef2d380a9848dd | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.28e-04 | 177 | 6 | 2 | 4943d040eee0f9dceaddc7498171281d170e271f | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(non-nasal)-Club_(non-nasal)_L.0.4.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.28e-04 | 177 | 6 | 2 | a235ff4f37a7622216526191efc4832fb8ed6957 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.28e-04 | 177 | 6 | 2 | 3645e2f4a48283f290f85c49c3e79e3f58ac9aa6 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.28e-04 | 177 | 6 | 2 | a8625d14682183cf77cb51eaf11bc15a3528f586 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.28e-04 | 177 | 6 | 2 | 3f2272b577c862dba8ccfb41184054bbd0ace6f5 | |
| ToppCell | RA-07._Pericyte|RA / Chamber and Cluster_Paper | 2.39e-04 | 181 | 6 | 2 | 8dfb42d096db6c2df9b41303a7199d134d4bff07 | |
| ToppCell | COVID-19-Heart-Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.39e-04 | 181 | 6 | 2 | 33cac65ed1ea5e7bd72250495df4f850b143d5aa | |
| ToppCell | RA-07._Pericyte|World / Chamber and Cluster_Paper | 2.42e-04 | 182 | 6 | 2 | 2075efeae633550fb2eb026d0dfd741c8252482e | |
| ToppCell | COVID-19-Heart-EC_+_Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.42e-04 | 182 | 6 | 2 | e67f3234165199085c793915ebb1f9bbd845e933 | |
| ToppCell | LV-07._Pericyte|World / Chamber and Cluster_Paper | 2.44e-04 | 183 | 6 | 2 | 273db6a3b00a93ca852498471187b642b5368185 | |
| ToppCell | LA-07._Pericyte|World / Chamber and Cluster_Paper | 2.44e-04 | 183 | 6 | 2 | e3835db4795362b0442d5893baf2a78efcc20428 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.44e-04 | 183 | 6 | 2 | 667717366cb181b8a04a347e64f0f5a4dfc6ee7f | |
| ToppCell | COVID-19-Heart-Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 2.47e-04 | 184 | 6 | 2 | 21790cdfa3b4036ad413fd44b94e31563116f25f | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.50e-04 | 185 | 6 | 2 | a8ca7819066d5297ef6966e7f3e2c9f8a7673fdc | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.50e-04 | 185 | 6 | 2 | 7092436b4db90289516ed130ade596e3021cffaf | |
| ToppCell | LA-07._Pericyte|LA / Chamber and Cluster_Paper | 2.50e-04 | 185 | 6 | 2 | ba5baa4d7f097108622674de5b7f4fd279843d24 | |
| ToppCell | human_hepatoblastoma-Hepatic_Stellate_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 2.52e-04 | 186 | 6 | 2 | cb1fc4b9140666b43415e21c9b434dc9b144e9d0 | |
| ToppCell | normal_Lung-Myeloid_cells-pDCs|Myeloid_cells / Location, Cell class and cell subclass | 2.55e-04 | 187 | 6 | 2 | a3592f056e1c2f82ba325fea2ecc4dd6c6347c81 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.55e-04 | 187 | 6 | 2 | ec4b694487cc446999c7b27b119950a4f252c4b3 | |
| ToppCell | normal_Lung-Myeloid_cells-pDCs|normal_Lung / Location, Cell class and cell subclass | 2.55e-04 | 187 | 6 | 2 | d36751372fd40a46441f07735c9c3c5dcb503f24 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.55e-04 | 187 | 6 | 2 | 530e4e6d91b5c0d9aa4543caa2b734a1674c5788 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.55e-04 | 187 | 6 | 2 | 958402fcc78f4c7a7d13d659d776f3817137975f | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.55e-04 | 187 | 6 | 2 | 48bfdb3504c3fefe5db3abac4b790c369680ab4e | |
| ToppCell | COVID-19-Epithelial-Ionocytes|COVID-19 / Condition, Lineage and Cell class | 2.58e-04 | 188 | 6 | 2 | a581cb9528d0febbf3addbb4f6bc140f91a584e6 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.60e-04 | 189 | 6 | 2 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.60e-04 | 189 | 6 | 2 | fac5c291a9a87418bb0878c3d624829bdbf1f428 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.63e-04 | 190 | 6 | 2 | 5681c211baeed4af82a2bbc13420f6a7b487581c | |
| ToppCell | human_hepatoblastoma-Hepatic_Stellate_cells|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells) | 2.66e-04 | 191 | 6 | 2 | 78c3c2fdb68c3407f2436f90e1e6a780bbf8b79e | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.66e-04 | 191 | 6 | 2 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM1_(8)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 2.69e-04 | 192 | 6 | 2 | 4c9d748f209cc1e13d28c8c7f5180ab8522e0fbf | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-04 | 192 | 6 | 2 | 6f4ef24dab544681304b7f8a9dc073e7edaa4cf5 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.69e-04 | 192 | 6 | 2 | 24e2f15f5767a97eb3b389922bcfd7b13805e1ce | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM1_(8)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.72e-04 | 193 | 6 | 2 | e2b455387d1de7812305200a2041a0f4759a6f54 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.72e-04 | 193 | 6 | 2 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM1_(8)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.74e-04 | 194 | 6 | 2 | fb80a0271ccb1cb3f954ebcf2c5945cb6adb6b8c | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.74e-04 | 194 | 6 | 2 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.74e-04 | 194 | 6 | 2 | e93de9428c986b8943fc169258847c650cfab0e5 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_adventitial_fibro_(9)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.74e-04 | 194 | 6 | 2 | 5f5f0cdeacd5e1b28717d78dabdb9eb95f661e36 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.74e-04 | 194 | 6 | 2 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | PCW_07-8.5-Mesenchymal|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.80e-04 | 196 | 6 | 2 | 8e10802f52e5e1853ea4ad34bf9a32a34e6112b5 | |
| ToppCell | PCW_05-06-Mesenchymal|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.80e-04 | 196 | 6 | 2 | dca52c57ba35d9395cdbca8b881f12ece721b10f | |
| ToppCell | LPS_IL1RA_TNF|World / Treatment groups by lineage, cell group, cell type | 2.83e-04 | 197 | 6 | 2 | 0a6550dce156fc81f15b1e7830d331ca50d87d06 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 2.86e-04 | 198 | 6 | 2 | 0c4d2c68a42f8a9e964e2dd28092fe75f5216834 | |
| ToppCell | background-Hepatic_Stellate_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 2.86e-04 | 198 | 6 | 2 | 79f32f965aed6a10c5cb803173e3db7b32e07a91 | |
| ToppCell | 10x3'2.3-week_14-16-Mesenchymal_osteo-stroma-early_osteoblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 2.86e-04 | 198 | 6 | 2 | 6a539d3b47bd2d4a7ad5c67cad23facffc0ac45f | |
| ToppCell | background-Hepatic_Stellate_cells|background / Sample and Cell Type and Tumor Cluster (all cells) | 2.86e-04 | 198 | 6 | 2 | bd11b0e9e80449aab979a02c1023e0638c431c7c | |
| Drug | Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Up 200; 21uM; MCF7; HT_HG-U133A | 4.51e-04 | 199 | 4 | 2 | 4159_UP | |
| Drug | O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate | 5.07e-04 | 211 | 4 | 2 | ctd:C009618 | |
| Drug | Lithium Chloride | 1.22e-03 | 328 | 4 | 2 | ctd:D018021 | |
| Drug | Grape Seed Proanthocyanidins | 7.98e-03 | 852 | 4 | 2 | ctd:C511402 | |
| Drug | Catechin | 9.43e-03 | 928 | 4 | 2 | ctd:D002392 | |
| Drug | panobinostat | 1.90e-02 | 1333 | 4 | 2 | ctd:C496932 | |
| Disease | colon cancer (implicated_via_orthology) | 3.85e-10 | 11 | 5 | 3 | DOID:219 (implicated_via_orthology) | |
| Disease | precuneus cortex volume measurement | 2.09e-06 | 14 | 5 | 2 | EFO_0010326 | |
| Disease | cleft lip | 9.06e-04 | 284 | 5 | 2 | EFO_0003959 | |
| Disease | diet measurement | 1.18e-02 | 1049 | 5 | 2 | EFO_0008111 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GQWQEWSSWSQCSVT | 401 | O60242 | |
| WSNHSWNTQTWCTQS | 216 | Q9H9S0 | |
| WSNHSWNTQTWCTQS | 216 | Q6NSW7 | |
| HTVNGAWSAWTSWSQ | 781 | Q13591 | |
| WVAAHWTTSQSCAAW | 96 | Q96NS8 | |
| QSWSNHSWNTQTWCT | 141 | Q8N7R0 | |
| HSWNTQTWCTQSWNN | 146 | Q8N7R0 |